The FDA approved VEPPANU (vepdegestrant) for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer following at least one line of endocrine therapy. VEPPANU is the first-and-only FDA-approved PROTAC protein degrader. Approval was granted ahead of the June 5, 2026, PDUFA date. Arvinas will receive a $50 million development milestone payment from its collaboration with Pfizer. The company and Pfizer are currently selecting a third-party partner for commercialization.